Wall Street Zen Upgrades Paysign (NASDAQ:PAYS) to "Buy"
Wall Street Zen has upgraded Paysign (NASDAQ:PAYS) from a "hold" to a "buy" rating, leading to a consensus "Moderate Buy" rating among analysts with an average price target of $8.56. This upgrade follows Paysign's reported quarterly EPS of $0.04, which met estimates, and revenue of $21.6 million, exceeding analysts' expectations. The article also notes recent insider selling activity and institutional investment in the company.
New York State Common Retirement Fund Raises Stake in Paysign, Inc. $PAYS
The New York State Common Retirement Fund significantly increased its stake in Paysign, Inc. (NASDAQ:PAYS) by 2,943.3% in the third quarter of 2025, now holding 385,732 shares valued at approximately $2.43 million. Other institutional investors also adjusted their positions, and analysts maintain a "Moderate Buy" rating for Paysign with a consensus target price of $8.56. Paysign reported strong Q3 earnings, meeting EPS expectations and beating revenue forecasts, and provided positive FY2025 EPS guidance.
The Price Is Right For Paysign, Inc. (NASDAQ:PAYS) Even After Diving 27%
Paysign, Inc. (NASDAQ:PAYS) has experienced a 27% share price drop in the last month, though it's still up 37% over the past year. Despite its current high P/E ratio compared to the market, analysts forecast stronger earnings growth for Paysign than the general market, which may justify its higher valuation to investors. The article suggests that investors are focusing on the company's anticipated future growth rather than its recent dips in performance.
Paysign, Inc. (NASDAQ:PAYS) Given Average Rating of "Moderate Buy" by Analysts
Paysign, Inc. (NASDAQ:PAYS) has received an average "Moderate Buy" rating from five analysts, with a 1-year average target price of $8.56. Insider Robert Strobo recently sold 20,000 shares, reducing his holding by 5.76%. The company's latest quarterly earnings saw EPS of $0.04 and revenue of $21.6M, exceeding revenue estimates, and FY2025 EPS guidance is set at $0.120-$0.130.
Palisades Investment Partners LLC Buys Shares of 897,634 Paysign, Inc. $PAYS
Palisades Investment Partners LLC acquired a new position of 897,634 shares of Paysign, Inc. (NASDAQ:PAYS) during the third quarter, valued at approximately $5.65 million, making it their 19th-largest holding. Paysign has a "Moderate Buy" consensus rating from analysts with an average target price of $8.56, and recently reported Q3 EPS of $0.04 and revenue of $21.6M. The company has a current market cap of about $248 million and has issued FY2025 EPS guidance of $0.120–0.130.
Paysign, Inc. to Present at the Oppenheimer 11th Annual Emerging Growth Conference
Paysign, Inc. (NASDAQ: PAYS), a fintech and healthcare company, announced its participation in the Oppenheimer 11th Annual Emerging Growth Conference on February 3-4, 2026. Paysign's CFO, Jeff Baker, will host one-on-one meetings to showcase the company's patient affordability programs, donor compensation solutions, and integrated payment processing for life sciences. The conference will feature emerging companies in technology, industrial growth, and consumer sectors in a virtual format.
Paysign, Inc. to Present at the Oppenheimer 11th Annual Emerging Growth Conference
Paysign, Inc. (NASDAQ: PAYS) announced its participation in the Oppenheimer 11th Annual Emerging Growth Conference, which will be held virtually on February 3-4, 2026. Paysign's CFO, Jeff Baker, will host one-on-one meetings on February 3rd. The conference focuses on emerging technology, industrial growth, and consumer sectors, providing an opportunity for investors to engage with Paysign, a company specializing in fintech and healthcare payment solutions.
Paysign, Inc. to Present at the Oppenheimer 11th Annual Emerging Growth Conference
Paysign, Inc. (NASDAQ: PAYS) announced its participation in the Oppenheimer 11th Annual Emerging Growth Conference, which will be held virtually on February 3-4, 2026. The company's Chief Financial Officer, Jeff Baker, will host one-on-one meetings with investors on February 3. Paysign specializes in fintech and healthcare, providing payment processing and program management for plasma, pharmaceutical, and life sciences industries.
Paysign to Present at Oppenheimer 11th Annual Emerging Growth Conference in February 2026
Paysign (PAYS) will present at the Oppenheimer 11th Annual Emerging Growth Conference virtually on February 3-4, 2026, with CFO Jeff Baker hosting one-on-one meetings. The company specializes in patient affordability and donor compensation solutions for the life sciences sector, leveraging proprietary payment processing technology. Analyst ratings show a positive outlook for PAYS, with an average 1-year price target of $9.00 among four analysts.
Paysign, Inc. to Present at the Oppenheimer 11th Annual Emerging Growth Conference
Paysign, Inc. (NASDAQ: PAYS) announced its participation in the Oppenheimer 11th Annual Emerging Growth Conference, which will take place virtually on February 3-4, 2026. Paysign's CFO, Jeff Baker, will host one-on-one meetings with investors interested in the company's fintech and healthcare solutions. The conference focuses on emerging companies in technology, industrial growth, and consumer sectors.
Paysign stock rating reiterated at Buy by DA Davidson on pharma growth
DA Davidson has reiterated its Buy rating and $9.00 price target for Paysign Inc. (NASDAQ:PAYS), citing robust growth in the company's pharmaceutical patient affordability programs. The firm predicts a 156% year-over-year increase in revenue from this segment for 2025, contributing significantly to Paysign's total revenue. This reiteration follows strong third-quarter earnings, where Paysign exceeded revenue and EPS forecasts.
Paysign stock rating reiterated at Buy by DA Davidson on pharma growth
DA Davidson has reiterated its Buy rating and $9.00 price target for Paysign Inc. (NASDAQ:PAYS), citing robust growth in the company's pharmaceutical patient affordability programs. The firm forecasts a 156% year-over-year increase in revenue from this segment for 2025, reaching $32.4 million and accounting for about 40% of total revenue. This reiteration follows strong third-quarter earnings where Paysign surpassed revenue and EPS expectations.
Paysign, Inc. Announces 2025 Performance Analysis of Patient Affordability Solutions
Paysign, Inc. (NASDAQ: PAYS) announced its 2025 performance analysis for patient affordability solutions, highlighting significant achievements in mitigating copay maximizers. The company saved pharmaceutical clients over $325 million and supported 131 programs, assisting more than 840,000 unique patients. Paysign credits its Dynamic Business Rules feature for accurately identifying impacted claims and delivering substantial value to both clients and patients by reducing healthcare costs.
Paysign stock rating reiterated at Buy by DA Davidson on pharma growth
DA Davidson has reaffirmed its Buy rating and $9.00 price target for Paysign Inc. (NASDAQ:PAYS), driven by significant growth in its pharmaceutical patient affordability programs. The company expanded its programs by 72% over the past year to 131, and its pharmaceutical segment is projected to contribute 40% of total revenue in 2025. This positive outlook follows strong third-quarter results, where Paysign exceeded revenue and EPS forecasts.
Lake Street Remains a Buy on PaySign (PAYS)
Lake Street analyst Jacob Stephan has reiterated a Buy rating on PaySign (PAYS) with a price target of $10.00. The recommendation is supported by PaySign's strong financial performance, reporting increased quarterly revenue of $21.6 million and a net profit of $2.22 million for the quarter ending September 30. The broader analyst consensus for PaySign remains a Strong Buy with an average price target of $9.00.
Paysign, Inc. Announces 2025 Performance Analysis of Patient Affordability Solutions
Paysign, Inc. announced its 2025 performance analysis for patient affordability programs, highlighting significant growth and savings. The company added 55 programs, ending 2025 with 131 active programs and saving pharmaceutical clients over $325 million by mitigating copay maximizers. Paysign's Dynamic Business Rules feature played a crucial role in these achievements, supporting more than 840,000 unique patients and assisting pharmaceutical clients with over $950 million in prescription fulfillment expenses.
D.A. Davidson Sticks to Its Buy Rating for PaySign (PAYS)
D.A. Davidson analyst Peter Heckmann reiterated a Buy rating for PaySign (PAYS) and maintained a $9.00 price target. This recommendation is supported by PaySign's strong financial performance, reporting increased quarterly revenue of $21.6 million and a net profit of $2.22 million for the quarter ending September 30, compared to the previous year. The broader analyst consensus for PaySign also stands at a Strong Buy with an average price target of $9.00.
Paysign stock rating reiterated at Buy by DA Davidson on pharma growth
DA Davidson has reiterated its Buy rating and $9.00 price target for Paysign Inc. (NASDAQ:PAYS), citing robust growth in the company's pharmaceutical patient affordability programs. The firm noted a 72% increase in programs over the past year, with an anticipated 156% year-over-year revenue growth from this segment for 2025. This positive outlook follows strong third-quarter earnings, where Paysign exceeded expectations for both EPS and revenue.
Paysign, Inc. Announces 2025 Performance Analysis of Patient Affordability Solutions
Paysign, Inc. announced its 2025 performance analysis for its patient affordability programs, highlighting significant savings for pharmaceutical clients. The company prevented over $325 million in funds diversion by mitigating copay maximizers and supported 131 retail and specialty pharmaceutical programs. Paysign's Dynamic Business Rules achieved 97% accuracy in identifying impacted claims, assisting over 840,000 unique patients and delivering more than $950 million towards prescription fulfillment expenses.
Paysign, Inc. (NASDAQ:PAYS) Receives Consensus Rating of "Moderate Buy" from Analysts
Paysign, Inc. (NASDAQ:PAYS) has received a consensus "Moderate Buy" rating from analysts, with an average 12-month price target of $8.56. Recent analyst updates include a $9 target from DA Davidson and a "buy" upgrade from Wall Street Zen. The company reported in-line Q earnings and beat revenue expectations, setting FY2025 EPS guidance of $0.120-$0.130.
OppFi Trades Cheaper Than Its Peers: Is This a Potential Value Play?
OppFi (OPFI) presents a compelling "value play" due to its strong financial performance, upbeat outlook, and significantly lower price-to-earnings ratio compared to its peers. The company has raised its adjusted net income and EPS guidance for 2025, supported by improved auto approval rates and a secured revolving credit facility with better interest rates. Additionally, OppFi shows robust liquidity and a decline in net charge-offs, positioning it as a high-growth-oriented stock despite recent underperformance against one competitor.
Wall Street Analysts Believe Paysign (PAYS) Could Rally 65.76%: Here's is How to Trade
Wall Street analysts are optimistic about Paysign (PAYS), projecting a potential upside of 65.76%. This forecast is based on an average price target derived from recent analyst ratings, suggesting a strong consensus for future growth. Investors interested in PAYS will find this analysis helpful for their trading decisions.
Are Business Services Stocks Lagging Paysign (PAYS) This Year?
Paysign, Inc. (PAYS) has significantly outperformed the Business Services sector year-to-date, returning 81.8% compared to the sector's average loss of 7.6%. This strong performance is supported by a Zacks Rank #2 (Buy) and a 2.9% increase in its full-year earnings consensus estimate. Rollins (ROL), another stock in the sector, has also shown strong performance, returning 29.6% year-to-date.
Wall Street Analysts Believe Paysign (PAYS) Could Rally 65.76%: Here's is How to Trade
Wall Street analysts anticipate a significant upside for Paysign (PAYS), with a mean price target indicating a potential 65.8% rally. Although relying solely on price targets can be misleading, the strong agreement among analysts and positive earnings estimate revisions suggest a legitimate reason for optimism. PAYS currently holds a Zacks Rank #2 (Buy), further strengthening the case for potential near-term growth.
Paysign Executive Offloads Shares Under Pre-Arranged Trading Plan
Robert Strobo, Paysign's Chief Legal Officer, sold 20,000 shares worth approximately $109,400 under a pre-arranged Rule 10b5-1 trading plan. This transaction represents a 5.76% decrease in his direct holdings, though he still retains significant shares. The sale aligns with a broader trend of insider selling outweighing buying at Paysign over the past year, despite a "Moderate Buy" or "Strong Buy" analyst consensus for the company.
Robert Strobo Sells 20,000 Shares of Paysign (NASDAQ:PAYS) Stock
Robert Strobo, an insider at Paysign (NASDAQ:PAYS), sold 20,000 shares of the company's stock for a total of $109,400, reducing his stake by 5.76%. Paysign recently reported Q3 EPS of $0.04, matching estimates, and revenue of $21.6M, exceeding expectations. The company has a "Moderate Buy" consensus rating from analysts with an average price target of $8.56.
Paysign’s chief legal officer Strobo sells $109,400 in stock
Paysign's Chief Legal Officer, Robert Strobo, sold 20,000 shares of the company's common stock for $109,400 on December 12, 2025. This transaction was conducted under a Rule 1
Insider Selling: Robert Strobo Sells 20,000 Shares of PaySign In
Robert Strobo, Chief Legal Officer of PaySign Inc's subsidiary, sold 20,000 shares of PaySign Inc (PAYS) on December 12, 2025, bringing his total ownership down to 327,290 shares. Over the past year, Strobo has sold 46,521 shares and made no purchases. The stock is currently priced at $5.47, indicating it is modestly overvalued based on GuruFocus's GF Value of $4.92.
Paysign’s chief legal officer Strobo sells $109,400 in stock
Paysign's Chief Legal Officer Robert Strobo sold 20,000 shares of common stock for $109,400 on December 12, 2025, according to a Rule 10b5-1 trading plan. Despite this insider sale, PAYS stock has surged 81.79% year-to-date and analyst targets range from $8.50 to $10.00. The company recently reported strong Q3 earnings, surpassing revenue and EPS forecasts, and DA Davidson reiterated a Buy rating with a $9 price target.
Paysign, Inc. Just Beat EPS By 100%: Here's What Analysts Think Will Happen Next
Paysign, Inc. (NASDAQ:PAYS) recently reported a significant beat on its quarterly earnings per share (EPS) by 100% and revenue exceeding estimates by 8.4%. Despite analysts slightly downgrading EPS forecasts for 2026, they maintained revenue estimates and increased the consensus price target by 8.3% to US$9.10, indicating continued confidence in the company's long-term prospects and its potential for growth that outpaces the industry.
Paysign, Inc. Reports Third Quarter 2025 Financial Results
Paysign, Inc. announced record-breaking financial results for the third quarter of 2025, with revenue soaring 41.6% year-over-year to $21.6 million and Adjusted EBITDA up 78.1% to $5.0 million. The growth was primarily driven by a 141.9% increase in its pharma patient affordability business, complemented by a 12.4% rise in its plasma donor compensation business. The company also raised its full-year 2025 outlook, projecting total revenues between $80.5 million and $81.5 million.
Paysign, Inc. Reports Third Quarter 2025 Financial Results
Paysign, Inc. (NASDAQ: PAYS) announced strong financial results for the third quarter of 2025, with record revenue of $21.60 million, a 41.6% increase year-over-year, and improved profitability including a 54.2% rise in net income to $2.22 million. The company's pharma patient affordability business saw significant growth of 141.9%, outperforming expectations, while the plasma donor compensation business also returned to year-over-year growth. Paysign raised its full-year 2025 financial outlook, anticipating total revenues between $80.5 million and $81.5 million.
120,689 Shares in Paysign, Inc. $PAYS Bought by Connor Clark & Lunn Investment Management Ltd.
Connor Clark & Lunn Investment Management Ltd. recently purchased 120,689 shares of Paysign, Inc. (NASDAQ:PAYS) valued at approximately $869,000, now owning about 0.22% of the company. Paysign reported strong Q3 results, meeting EPS estimates and exceeding revenue forecasts, with analysts maintaining a "Moderate Buy" rating and an average target price of $8.56. The company’s stock performance shows a 52-week range of $1.80 to $8.88, and it has provided positive FY2025 guidance.
Paysign, Inc. Just Recorded A 100% EPS Beat: Here's What Analysts Are Forecasting Next
Paysign, Inc. (NASDAQ:PAYS) exceeded revenue and EPS forecasts in its latest results, with revenue at US$22m and EPS at US$0.04. Despite a slight dip in future EPS forecasts by analysts, the price target for the stock has been increased by 8.3% to US$9.10. The company is expected to continue its historical growth trend, growing significantly faster than its industry peers.
Paysign, Inc. to Present at the 17th Annual Southwest IDEAS Investor Conference
Paysign, Inc. will present at the 17th Annual Southwest IDEAS Investor Conference on November 19-20, 2025, in Dallas, Texas. CFO Jeff Baker will represent the company, which specializes in patient affordability programs and payment processing for the life sciences industries. This invitation-only event connects public companies with institutional investors through one-on-one and group meetings.
Paysign, Inc. Just Beat EPS By 100%: Here's What Analysts Think Will Happen Next
Paysign, Inc. achieved strong Q3 results, beating revenue and EPS forecasts significantly. Following this, analysts slightly lowered EPS forecasts for 2026 but maintained revenue estimates, noting the company's expected revenue growth surpassing the industry average. The consensus price target also increased, suggesting a positive long-term outlook despite minor adjustments to earnings per share.
PaySign, Inc. (NASDAQ:PAYS) Q3 2025 Earnings Call Transcript
PaySign (NASDAQ: PAYS) reported robust Q3 2025 results with record revenue of $21.6 million, up 41.6% year over year, and adjusted EBITDA of $5 million, an increase of 78%. The company’s patient affordability business saw exceptional growth, generating $7.9 million in revenue, a 142% increase, and aims to expand active programs significantly by year-end. PaySign also provided raised guidance for full-year 2025, projecting revenues between $80.5 million and $81.5 million and adjusted EBITDA in the range of $19 million to $20 million.
Paysign, Inc. SEC 10-Q Report
Paysign, Inc. (PAYS) released its Q3 2025 10-Q report, showcasing significant financial growth driven by its expanding presence in the pharmaceutical industry. The company reported substantial increases in total revenues, gross profit, income from operations, and net income, largely due to new pharma patient affordability programs. While pharma revenue surged, plasma industry revenue saw a slight decrease due to normalized inventory levels.
Paysign (NASDAQ: PAYS) CFO Jeff Baker to present; one-on-one meetings Nov 19–20 at IDEAS
Paysign, Inc. (NASDAQ: PAYS) announced its CFO, Jeff Baker, will present at the 17th Annual Southwest IDEAS Investor Conference on November 19 and 20, 2025, in Dallas, Texas. The conference is an invitation-only event designed to allow public companies to interact with institutional investors through one-on-one and group meetings. Paysign specializes in fintech and healthcare, offering patient affordability programs and donor compensation solutions.
What is the current Price Target and Forecast for Paysign (PAYS)
This article provides the current price targets and forecasts for Paysign (PAYS) based on analyst recommendations. It details the average price target, high and low forecasts, and the potential upside from the last closing price. Additionally, it includes the Zacks Rank, Style Scores, and Broker Rating for PAYS.
Financial Contrast: Paysign (NASDAQ:PAYS) and WEX (NYSE:WEX)
This article provides a financial comparison between Paysign (NASDAQ:PAYS) and WEX (NYSE:WEX), evaluating them across several metrics including profitability, valuation, institutional ownership, volatility, and analyst recommendations. While WEX exhibits higher revenue and earnings, Paysign is favored by analysts due to its stronger consensus rating and higher potential upside. The analysis concludes that WEX outperforms Paysign on 8 out of 14 compared factors.
Paysign to Host Third Quarter 2025 Earnings Call - PharmiWeb.com
Paysign, Inc. announced it will host its Third Quarter 2025 Earnings Call on November 7, 2025, to discuss financial results and provide a business update. The call will include a question and answer session for registered financial professionals, with details provided for participation and replay access. The article also includes forward-looking statements and contact information for investor and media relations.
Paysign to Host Third Quarter 2025 Earnings Call - 01net
Paysign, Inc. announced it will host its Third Quarter 2025 earnings call on November 9, 2025, at 5:00 p.m. ET. The call will discuss financial results which are expected to be released after market close on the same day. Details for participant dial-in, international access, webcast, and replay information are provided.
Total Clarity Wealth Management Inc. Buys Shares of 51,476 Paysign, Inc. $PAYS
Total Clarity Wealth Management Inc. recently acquired 51,476 shares of Paysign, Inc. (NASDAQ:PAYS) valued at approximately $371,000, increasing its stake to 0.09% of the company. This institutional buying contrasts with recent insider selling by Paysign's CFO and CEO. Wall Street analysts maintain a "Moderate Buy" rating for Paysign despite a recent earnings miss, with price targets ranging from $9.00 to $10.00.
Recent 15% pullback isn't enough to hurt long-term Paysign (NASDAQ:PAYS) shareholders, they're still up 154% over 3 years - Yahoo Finance
Despite a recent 15% share price drop in the last quarter, Paysign (NASDAQ:PAYS) shareholders have seen a strong 154% return over the past three years. The company has become profitable in this period, a factor that often drives significant share price gains. Insider buying also suggests continued confidence in the company's future performance.
Paysign, Inc. Announces Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions
Paysign, Inc. announced a summary notice regarding the pendency and proposed settlement of several stockholder derivative actions. These actions alleged that company officers breached fiduciary duties by issuing false statements and failing to disclose material facts, leading to reputational and financial harm. As part of the settlement, Paysign agrees to implement corporate governance reforms for five years, and defendants' insurers will pay $607,500 for plaintiffs' attorneys' fees and expenses.
Paysign, Inc. Announces Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions
Paysign, Inc. has announced a summary notice regarding the pendency and proposed settlement of stockholder derivative actions. These actions, alleging fiduciary duty breaches and misleading statements by individual defendants between March 2019 and September 2020, will be settled through the implementation of corporate governance reforms by Paysign for five years. A settlement hearing is scheduled for November 14, 2025, to approve the settlement terms, including attorney's fees and service awards for the plaintiffs.
Paysign, Inc. Opens 30,000 Square Foot Patient Service Support Center to Meet Growing Demand in Patient Affordability Business
Paysign, Inc. has opened a new 30,000 square foot patient service support center in Henderson, Nevada, quadrupling its support capacity. This expansion is driven by the rapid growth in demand for Paysign's patient affordability solutions, particularly its Dynamic Business Rules technology, which optimizes copay assistance programs. The new center will also allow for expanded support offerings, including dedicated specialists for individual programs, as Paysign's patient affordability business saw a 190% year-over-year revenue increase in Q2 2025.
Paysign, Inc. Announces Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions
Paysign, Inc. announced a summary notice of pendency and proposed settlement of several stockholder derivative actions. These actions alleged breaches of fiduciary duties by individual defendants related to false and misleading statements, internal control failures, and insider sales. As part of the settlement, Paysign agrees to implement corporate governance reforms for five years, and the defendants' insurers will pay $607,500.00 for attorneys' fees and expenses.
Paysign names Dan Henry as new board chairman By Investing.com
Paysign, Inc. (NASDAQ:PAYS) has appointed Dan Henry as its new Chairman of the Board, succeeding Mark Newcomer who will continue as President and CEO. Henry brings over 30 years of fintech experience, including leadership roles at Euronet Worldwide and NetSpend Corporation. This change aligns with Paysign's focus on growth in healthcare payment solutions, while Euronet (not directly related to Paysign's announcement) recently reported Q2 2025 earnings below expectations and announced a private placement of convertible senior notes.
